Showing posts with label medicine. Show all posts
Showing posts with label medicine. Show all posts

Tuesday, February 18, 2020

low cost portable MRI

FDA Clears 'World's First' Portable, Low-Cost MRI Following Positive Clinical Research (healthimaging.com)25

Magnetic resonance imaging is no longer confined to radiology departments. The U.S. Food and Drug Administration announced this month that it has provided clearance to the "world's first" bedside MRI system, according to an announcement. From a report:Hyperfine said it will begin shipping its portable, low-field modalities this summer. It's 510(k) clearance falls on the same day that Yale researchers reported the device can accurately and safely image patient's brains for stroke. Those preliminary results are set to be presented next week at the American Stroke Association's International conference in Los Angeles, the group announced. "We've flipped the concept from having to get patients to the MRI to bringing the MRI to the patients," said Kevin Sheth, MD, senior author and a chief physician at Yale School of Medicine. "This early work suggests our approach is safe and viable in a complex clinical care environment."

The study included 85 stroke patients who underwent bedside MRI within seven days of experiencing symptoms. A majority of individuals completed the exam, which took an average of 30 minutes. Six experienced claustrophobia and a few couldn't fit into the machine, but there were no adverse events. According to Connecticut-based Hyperfine, their machine will cost $50,000, which is 20-times cheaper than traditional systems, runs on 35-times less power and weights 10 times less than normal 1.5T MRI machines.

Thursday, December 12, 2019

Low-Risk Ultrasound Procedure Destroys 80 Percent of Prostate Cancers In One-Year Study

Low-Risk Ultrasound Procedure Destroys 80 Percent of Prostate Cancers In One-Year Study (slashgear.com)54

An anonymous reader quotes a report from SlashGear:A new treatment shows promise for revolutionizing prostate cancer treatment, offering a minimally-invasive and relatively low-risk alternative to traditional surgeries and radiotherapies. Called TULSA, this method uses sound waves to eliminate the diseased tissue in the prostate, leaving the rest of the healthy tissues behind. According to the researchers, patients treated with this method experience "minimal side effects." The transurethral ultrasound ablation (TULSA) method uses an MRI to guide the procedure, which involves inserting a rod through the urethra into the prostate, where it uses heat via sound waves to destroy the cancerous tissues. Unlike the surgery typically used to treat this condition, TULSA is minimally invasive and can be performed as an outpatient procedure.

Using guided and controlled sound waves, doctors are able to preserve the nerves near the prostate while eliminating the diseased tissues using a total of 10 elements located on the insertable rod. A software algorithm is part of the system -- it controls the strength, direction, and shape of the ultrasound beam, though doctors watch carefully using the MRI in real-time. A new study involving 115 men found that the average treatment time for this procedure is a bit less than an hour. The researchers found that 80-percent of patients experienced elimination of "clinically significant" cancer and that 72 of the men had no signs of cancer after the first year. As well, incontinence was a very rare side effect of the procedure, which also had low instances of impotence.

Wednesday, November 27, 2019

Psilocybin For Major Depression Granted Breakthrough Therapy By FDA

Psilocybin For Major Depression Granted Breakthrough Therapy By FDA61

An anonymous reader quotes a report from New Atlas:The US Food and Drug Administration (FDA) has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD). This new FDA Breakthrough Therapy approval focuses on a seven-site, Phase 2 trial currently underway in the United States. Coordinated by a non-profit research organization called the Usona Institute, the trial is exploring the antidepressant properties of a single psilocybin dose in treating patients with major depressive disorder.

Last year's Breakthrough Therapy designation was targeted at the drug's efficacy for treatment-resistant depression (TRD). That particular clinical classification categorizes patients suffering from MDD who have not responded effectively to at least two different pharmacological antidepressant treatments during a current depressive episode. It is estimated between 10 and 30 percent of MDD patients fall into the category of TRD. The new FDA approval focuses on Usona's research into the broader condition of MDD, characterized by episodes of severe depression that last more than two weeks. Hundreds of millions of people around the world suffer from these kinds of acute major depressive episodes every year.
"The Usona Phase 2 trial plans to enrol 80 subjects, randomized to receive either a single active dose of psilocybin or an active placebo containing niacin," the report adds. "The methodology being trialed is similar to other psilocybin therapy studies, with a number of preparatory psychotherapy sessions preceding the active psychedelic dose, and a number of integrative psychotherapy sessions afterwards." It's estimated that the current Phase 2 trial will be completed by early 2021, where it should be able to move into larger Phase 3 trials if the results are positive.

The FDA also gave psilocybin therapy a Breakthrough Therapy status late last year. These trials should be completed sometime in 2020, "suggesting the next 12 to 24 months will offer some compelling and solid data into how effective this new psychedelic therapy actually is in treating several different forms of depression," reports New Atlas.

Friday, May 25, 2018

MIT gut sensor / smartphone app

Researchers have devised a new way to get a sneak peek into what's going on deep in your digestive system, creating a swallowable sensor that, with the help of engineered bacteria and a tiny electrical circuit, can detect the presence of molecules that might be signs of disease and then beam the results to a smartphone app. The device, which scientists validated in pigs, remains a prototype and needs to be refined before it could be used in people. But the researchers, who reported their work Thursday in the journal Science, combined innovations in synthetic biology and microelectronics to create a modular platform that could be adapted to identify a wide range of molecules. "We want to try to illuminate and provide understanding into areas that are not easily accessible," said Dr. Timothy Lu, a bioengineer at the Massachusetts Institute of Technology and senior author of the paper.

Monday, August 7, 2017

Tissue Nanotransfection (TNT): New device can heal with a single touch, and even repair brain injuries

https://www.usatoday.com/story/news/nation-now/2017/08/07/miracle-device-can-heal-single-touch-and-even-repair-brain-injuries/537326001/

New device can heal with a single touch, and even repair brain injuries

And, it not only works on skin cells, it can restore any type of tissue, Chandan Sen, director of the Center for Regenerative Medicine and Cell-Based Therapies, said. For example, the technology restored brain function in a mouse who suffered a stroke by growing brain cells on its skin.  
This is a breakthrough technology, because it's the first time cells have been reprogrammed in a live body. Current cell therapy methods are high risk, like those that introduce a virus, and include multiple steps, a new study published in Nature Nanotechnology points out. There are no known side effects to TNT and treatment is less than a second, Sen said.
“This technology does not require a laboratory or hospital and can actually be executed in the field," Sen said. "It’s less than 100 grams to carry and will have a long shelf life.” 
It is awaiting FDA approval, but Sen, who has been working on this for four years, expects TNT will be tested on humans within the year. He says he's talking with Walter Reed National Medical Center now. 
"We are proposing the use of skin as an agricultural land where you can essentially grow any cell of interest," Sen said.
Follow Ashley May on Twitter: @AshleyMayTweets
And, it not only works on skin cells, it can restore any type of tissue, Chandan Sen, director of the Center for Regenerative Medicine and Cell-Based Therapies, said. For example, the technology restored brain function in a mouse who suffered a stroke by growing brain cells on its skin.  
This is a breakthrough technology, because it's the first time cells have been reprogrammed in a live body. Current cell therapy methods are high risk, like those that introduce a virus, and include multiple steps, a new study published in Nature Nanotechnology points out. There are no known side effects to TNT and treatment is less than a second, Sen said.
“This technology does not require a laboratory or hospital and can actually be executed in the field," Sen said. "It’s less than 100 grams to carry and will have a long shelf life.” 
It is awaiting FDA approval, but Sen, who has been working on this for four years, expects TNT will be tested on humans within the year. He says he's talking with Walter Reed National Medical Center now. 
"We are proposing the use of skin as an agricultural land where you can essentially grow any cell of interest," Sen said.
Follow Ashley May on Twitter: @AshleyMayTweets

Sunday, June 11, 2017

Cancer drug

https://www.nytimes.com/2017/06/08/health/cancer-drug-keytruda-tumors.html

Photo
Adrienne Skinner of Larchmont, N.Y., had an extraordinarily rare and deadly cancer with no standard treatment. She started taking Keytruda in 2014 and her tumor is gone. CreditWhitten Sabbatini for The New York Times
The 86 cancer patients were a disparate group, with tumors of the pancreas, prostate, uterus or bone. One woman had a cancer so rare there were no tested treatments. She was told to get her affairs in order.
Still, these patients had a few things in common. All had advanced disease that had resisted every standard treatment.
All carried genetic mutations that disrupted the ability of cells to fix damaged DNA. And all were enrolled in a trial of a drug that helps the immune system attack tumors.
The results, published on Thursday in the journal Science, are so striking that the Food and Drug Administration already has approved the drug, pembrolizumab, brand name Keytruda, for patients whose cancers arise from the same genetic abnormality.
Continue reading the main story
“This is absolutely brilliant,” said Dr. José Baselga, physician in chief at Memorial Sloan Kettering Cancer Center in New York, which has just hired the study’s lead investigator, Dr. Luis A. Diaz Jr.
After taking pembrolizumab, 66 patients had their tumors shrink substantially and stabilize, instead of continuing to grow. Among them were 18 patients whose tumors vanished and have not returned.
There was no control group, which meant the results had to be absolutely compelling to be convincing. The study started in 2013 and is funded by philanthropies; the drugmaker’s only role was to supply the drug. The study is continuing.
The drug, made by Merck, is already on the market for select patients with a few types of advanced lung, melanoma and bladder tumors. It is expensive, costing $156,000 a year.
A test for the mutations targeted by the drug is already available, too, for $300 to $600.
Just 4 percent of cancer patients have the type of genetic aberration susceptible to pembrolizumab. But that adds up to a lot of patients: as many as 60,000 each year in the United States alone, the study’s investigators estimated.
Clinicians have long been accustomed to classifying cancers by their location in the body — patients are diagnosed with lung cancer, for example, or brain cancer.
Yet researchers have been saying for years that what matters was the genetic mutation causing the tumors. At first, they were certain they would be able to cure cancers with drugs that zeroed in on the mutations, wherever the tumors were lodged.
But cancers were more complicated than that, said Dr. Drew M. Pardoll, director of the Johns Hopkins Bloomberg-Kimmel Institute and an author of the new paper.
A mutation that appeared in half of all melanomas, for example, turned out to be rare in other cancers. And even when scientists pinpointed that mutation in 10 percent of colon cancers, the drug that worked for melanoma patients did not work for other cancer patients.
“It was a great dream,” Dr. Pardoll sighed.
The new study was based on a different idea. The immune system can recognize cancer cells as foreign and destroy them. But tumors deflect the attack by shielding proteins on their surface, making them invisible to the immune system.
Pembroluzimab is a new type of immunotherapy drug known as a PD-1 blocker, which unmasks the cancer cells so that the immune system can find and destroy them.
The drug is the happy result of a failed trial. A nearly identical drug, nivolumab, was given to 33 colon cancer patients, and just one showed any response — but his cancer vanished altogether.
What was special about that one patient? Dr. Diaz, a geneticist at Johns Hopkins until now, and lead author of the new study, found the answer: a genetic mutation that prevented the tumor from repairing DNA damage.
As a result, the man’s cancer cells contained a plethora of mutated genes, which produced thousands of strange-looking proteins on the surfaces of the cells. Once the tumor’s cloaking mechanism was short-circuited by the drug, the man’s immune system had no trouble targeting the foreign proteins on the cancer cells.
That led to the idea for the Dr. Diaz’s new study. He and his colleagues sought patients whose tumors had the same genetic defect, which can arise in any of four genes in a pathway that repairs damaged DNA. They gave these patients a PD-1 blocker and were surprised by the results.
The drug’s effects have been so durable that the investigators do not know how long the results should be expected to persist or how long these patients might expect to survive. That kind of result, Dr. Baselga said, “is insane.”
One patient in the study, Adrienne Skinner, 60, of Larchmont, N.Y., had an extraordinarily rare and deadly cancer, ampullary cancer, that arises at the end of the bile duct. There is no standard treatment, and the prognosis is dire.
Her doctors scheduled her for a drastic surgery that removes part of the pancreas, part of the small intestine, and the gall bladder. But her surgeon canceled the operation when he discovered her cancer had invaded her liver.
She tried chemotherapy instead — six months of one kind, then six months of another. Neither worked.
Then she qualified for Dr. Diaz’s clinical trial at Johns Hopkins. On April 15, 2014, Ms. Skinner had her first dose of the drug.
In July, her doctor inserted an endoscope for another biopsy. He turned to Ms. Skinner and said, “If someone hadn’t told me you have ampullary cancer, I would not have known.” The tumor was gone.
The trial involved giving patients the drug for two years, so Ms. Skinner continued to take the drug as a sort of insurance. Last year, she stopped, and her cancer has not returned.
“In effect, I was cured within months,” she said. “I have a great life.”
But even this promising trial has left a thread dangling: Why didn’t all of the patients respond?
There is now a fervid search for the answer. “Multiple labs are looking like crazy,” Dr. Balsega said.

Wednesday, January 20, 2016

Head transplant, monkeys

https://www.newscientist.com/article/2073923-head-transplant-carried-out-on-monkey-claims-maverick-surgeon/

Head transplant carried out on monkey, claims maverick surgeon

The plan to perform a human head transplant is on track, says Sergio Canavero, after successful experiments on monkeys and mice

The head transplant juggernaut rolls on. Last year, maverick surgeon Sergio Canavero caused a worldwide storm when he revealed his plan to attempt a human head transplant to New Scientist. He claimed that the surgical protocol would be ready within two years and said he intended to offer the surgery as a treatment for complete paralysis.

Now, working with other scientists in China and South Korea, he claims to have moved closer to that goal with a series of experiments in animals and human cadavers.
“I would say we have plenty of data to go on,” says Canavero. “It’s important that people stop thinking this is impossible. This is absolutely possible and we’re working towards it.”


“Science through PR”

The work is described in seven papers set to be published in the journals Surgery and CNS Neuroscience & Therapeutics over the next few months. New Scientist has not seen the papers and has not been able verify the latest claims. The issue of CNS Neuroscience & Therapeutics will be guest-edited by one of Canavero’s collaborators.

The fact that Canavero has gone public with the latest results before the papers are published has raised eyebrows. “It’s science through public relations,” says Arthur Caplan, a bioethicist at New York University School of Medicine. “When it gets published in a peer-reviewed journal I’ll be interested. I think the rest of it is BS.”
Thomas Cochrane, a neurologist at Harvard Medical School’s Centre for Bioethics, agrees that Canavero’s premature disclosure is unorthodox. “It’s frowned upon for good reason,” he says. “It generates excitement before excitement is warranted. It distracts people from actual work that everyone can agree has a valid foundation. As far as I can tell, that operation has mostly been about publicity rather than the production of good science.”
Although we can’t verify them, New Scientist has seen images and videos of some of the procedures Canavero describes.

These include the video above of mice sniffing and moving their legs, apparently weeks after having the spinal cord in their necks severed and then re-fused. C-Yoon Kim, at Konkuk University School of Medicine in South Korea, who carried out the procedure, says his team have demonstrated the recovery of motor function in the forelimbs and hindlimbs of the animals. “Therefore I guess it is possible to reconnect the [spinal] cord after complete severance,” he says.

Canavero says Kim’s work shows that the spinal cord can re-fuse if it is cut cleanly in the presence of polyethylene glycol (PEG), a chemical that preserves nerve cell membranes. “These experiments prove once and for all that simply using PEG, you can see partial recovery,” he says.
As well as the use of PEG, the procedure Canavero outlines in the papers includes techniques to aid recovery such as spinal cord stimulation and the use of a negative pressure device to create a vacuum to encourage the nerves to fuse.


Fig.1b
Surgery/Ren/HEAVEN-AHBR
According to Canavero, researchers led by Xiaoping Ren at Harbin Medical University, China, have carried out a head transplant on a monkey. They connected up the blood supply between the head and the new body, but did not attempt to connect the spinal cord. Canavero says the experiment, which repeats the work of Robert White in the US in 1970, demonstrates that if the head is cooled to -15 °C, a monkey can survive the procedure without suffering brain injury.

“The monkey fully survived the procedure without any neurological injury of whatever kind,” says Canavero, adding that it was kept alive for only 20 hours after the procedure for ethical reasons. New Scientist was, however, unable to obtain further details on this experiment.
“We’ve done a pilot study testing some ideas about how to prevent injury,” says Ren, whose work is sponsored by the Chinese government. He and his team have also performed experiments on human cadavers in preparation for carrying out the surgery, he says.

Rich backers needed

Canavero is seeking funds to offer a head transplant to a 31-year-old Russian patient, Valery Spriridonov, who has a genetic muscle-wasting disease. Canavero says he intends to make a plea to Mark Zuckerberg to finance the surgery. Last week, Trinh Hong Son, director of the Vietnam-Germany Hospital in Hanoi, Vietnam, offered to host the procedure.
“If the so-called head transplant works, this is going to open up a whole new science of spinal cord trauma reconstruction,” says Michael Sarr, editor of the journal Surgery and a surgeon at the Mayo Clinic in Rochester, Minnesota. “We are most interested in spinal cord reconstruction using head transplantation as a proof of principle. Our journal does not necessarily support head transplantation because of multiple ethical issues and multiple considerations of informed consent and the possibility of negative consequences of a head transplant.”

Against the odds

Caplan says Canavero should study nerve regrowth with PEG in people with spinal cord injury before attempting a head transplant. “There are hundreds of thousands of people who could benefit from something that would regrow the spinal cord. It’s like saying I want to fly to the next galaxy when it would be nice to set up a colony on Mars, and I think about the same odds.”
Nevertheless, Canavero believes head transplantation is the only treatment that will work for paralysed patients. “Gene therapy has failed. Stem cells, we’re still waiting. Even if they come now, for these patients there is no hope. Tetraplegia can only be cured with this. Long term, the body decays, organs decay. You have to give them a new body because even if you take care of the cord, you’re going nowhere.”

Friday, December 25, 2015

UK 'Victorian' diseases - Immigration

http://www.pulseheadlines.com/uk-faces-alarming-rates-victorian-diseases/13672/

London – It has been mistakenly assumed that ancient diseases are totally eradicated, especially in developed countries. The United Kingdom particularly is now facing a “Victorian” disease epidemic, as cases of tuberculosis, scurvy, cholera, whooping cough, and scarlet fever are rising alarmingly. Experts believe the main causes could be immigration, malnutrition, poverty and lack of access to health care.

Dr. Nuria Martinez-Alier, an immunologist based in London, said that there has been a dramatic spike in scarlet fever, with 14,000 cases last year, the highest since the 1960s. According to the UK’s National Health Service (NHS), scarlet fever cases have increased 136%; cases of cholera have spiked 300% over the past five years; and, scurvy rates are up 38%. As for tuberculosis, diagnoses have decreased but rates are still disproportionately high, especially in some British neighborhoods where TB rates are even higher than in Guatemala, Iraq, Rwanda and other developing countries. Surprisingly, TB caused more global deaths this year than HIV and AIDS.

“Victorian” illnesses such as tuberculosis, cholera, and scarlet fever have been on the rise in the UK. 

Even though TB cases have been steadily decreasing also in the United States, on Tuesday, the White House published information about a new 5-year program to fight multidrug-resistant tuberculosis worldwide, after the World Health Organization (WHO) revealed the latest statistics on TB diagnosis and deaths. Named as the National Action Plan, the program involves efforts of governments of all affected nations, including partners from the private sector, as well as bilateral and multilateral partners.
 
Margaret Chan, Director-General of the WHO, commented that despite the fact that advances in TB control have helped save many lives around the world, leaders must encourage improvement in health care services and “critically invest in research” in order to definitely end the epidemic.

Malnutrition: A leading cause of severe diseases

British experts highlight the recent spike in malnutrition. It figures as the primary or secondary cause of admissions to the hospital, as the number of patients admitted with malnutrition has doubled in three years. Dianne Jeffrey, head of the Malnutrition Task Force, told earlier this year that professionals and the elderly mistakenly assume that it is normal to lose weight and have a reduced appetite as a consequence of aging.
“Much malnutrition is preventable, so it is totally unacceptable that estimates suggest there are at least one million older people malnourished or at risk of malnourishment,” expressed Jeffrey. “Cuts to social care mean many older people are being left to cope on their own.”

Raise awareness: Infectious diseases are not eradicated

Martinez-Alier warned that low vaccination rates significantly contribute to the problem. Of course, if people in this modern world believe that infectious diseases are a matter of history, no one will think of the importance of getting a vaccine against them. Most of the illnesses resurging today can be cured with medication. TB, for instance, can spread quickly and cause death if left untreated. In 2013, an estimated of 9 million cases of TB were reported worldwide, killing around 1.5 million people.
“I think there is a general sense in this country, at least for me — which is incorrect — that infectious diseases are completely eradicated, or that we found some way to get rid of them and that they are ‘Victorian’ illnesses,” said Josie Garrett, a London resident who is currently taking medication for TB. He added that people need to be aware of the fact that those diseases remain a threat.

Monday, December 14, 2015

Maternal exposure to anti-depressant SSRIs linked to autism in children

https://www.washingtonpost.com/news/to-your-health/wp/2015/12/14/maternal-exposure-to-anti-depressant-ssris-linked-to-autism-in-children/

A new study provides some of the strongest evidence yet that using an antidepressant like Prozac, Paxil or Zoloft during the final two trimesters of pregnancy may be linked to a higher risk of autism spectrum disorder for the child.

Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants, work by influencing naturally occurring chemical messengers in our brains.

The research, published in JAMA Pediatrics on Monday, involved the analysis of health records in Quebec from January 1999 and December 2009. During that time 145,456 full-term singleton infants were born, and 1,054 or 0.72 percent were subsequently diagnosed with autism. The average age at first diagnosis was 4.6 years and the average age of children at the end of follow-up was 6.2 years. Boys with autism outnumbered girls 4 to 1.

Researchers identified 4,724 infants (3.2 percent) who were exposed to antidepressants in utero, with 4,200 exposed ruing the first trimester; 2,532 during the second and/or third trimester.
Of the first group, 40 were diagnosed with autism and in the latter group 31 were diagnosed with autism.

When taking into account maternal depression as a factor, that translates to no association for use of antidepressants in the first trimester but an 87 percent  increased risk when used in the second or third trimester, Anick Bérard, a researcher at the University of Montreal, and co-authors wrote.
The researchers said that there may be several mechanisms at work that explain the phenomenon and it has to do with how serotonin impacts brain development. Scientists believe that the capacity of the brain to synthesize serotonin develops atypically in children with autism.

Due to the fact that antidepressants are "likely to remain widely used" in the future, "a better understanding of the long-term neurodevelopmental effects of [antidepressants] on children when used during gestation is a public health priority," Bérard wrote.

Doctors have long had mixed feelings about prescribing antidepressants to pregnant women. Previous studies have shown an increased risk of spontaneous abortion, prematurity and other physical issues and the U.S. Food and Drug Administration has wanted that one drug, Paxil, may increase the risk of birth defects.

But many doctors have tended to weigh the harms of maternal depression — which may lead to poor nutrition, avoidance of medical care among other issues — as potentially more directly damaging to a fetus than the drugs.

The new study may shift the conversation.

"What this tells us is that we need to think even more carefully about the prenatal environment. And not just about birth defects you can see at the time of delivery but about longer-term consequences," said Susan Hyman, a former chairperson of the American Academy of Pediatrics committee on autism, who is not affiliated with the study.

Surveys have shown that the use of SSRIs in pregnant women is rising in the United States — from less than 6 percent in 1999 to 13 percent in 2003 — and Hyman emphasized that the overwhelming majority of them do not have children with autism spectrum disorders.

"We would not want people to feel guilty," said Hyman, a professor of neurodevelopmental pediatrics at the University of Rochester Medical Center. "That is something that is not productive."
Scientists believe SSRIs balance the level of serotonin, which boosts mood for the mother. But the drugs also cross the placental barrier and the effect of such drugs on the brain development of a fetus at its earliest and more vulnerable state is still being studied.

The JAMA Pedatrics research adds to the growing number of studies about antidepressant and developmental delays, autism or Attention Deficit Hyperactivity Disorder  (ADHD) — but the picture is far from clear as the results have been mixed.

From a study design standpoint, the new study is stronger than some of the previous work because it is prospective, taking information about the pregnancies before they knew the outcome. But it has a number of limitations. First, the study used prescription filling data to determine which women were on antidepressants, but they may or may not have actually taken them. Perhaps more importantly, the data didn't have information about lifestyle, and it's possible that myriad factors, such as whether they smoke or their body mass index, may have influenced the findings.

Last April, Johns Hopkins University researchers reported in the journal Pediatrics that boys with autism were almost three times as likely to have been exposed to SSRIs than their typically developing counterparts. The team, which looked at nearly 1,000 mother-child pairs, found that the effect appeared to be stronger in those exposed during the first trimester and in boys than girls. A similar link was seen between a mother's SSRI use and developmental delays, but the sample was smaller and the researchers said those results should be interpreted with caution.

In another study, Harvard scientists analyzing electronic medical records reported that children who were exposed to antidepressants in the womb were at 80 percent increased risk of ADHD.

However, that same study found that children were not more likely to have autism spectrum disorders when accounting for a mother's medical history. That is, mothers with a history of psychiatric illness were more likely to have a child with autism regardless of whether or not they are on medication.
So if you're on antidepressants and pregnant or thinking about getting pregnant, what should you do?
Hyman said that it should still remain an individual decision, but that prospective mothers might want to have a serious discussion with their doctor about the possibility of other types of therapies for depression and anxiety, such as counseling.

Bryan H. King, a doctor at Seattle Children’s Hospital, had similar advice, writing in an editorial accompanying the study that "it makes no more sense to suggest that [antidepressants] should always be avoided than to say that they should never be stopped."

Thursday, December 10, 2015

Jimmy Carter Saved By Israeli Cancer Treatment

http://freebeacon.com/issues/jimmy-carter-saved-by-israeli-cancer-treatment/

BY:

Former president Jimmy Carter, who in the past has been supportive of boycotts against Israel, is having his cancer treated by a “breakthrough” drug created in the Jewish state, according to reports.
Carter, who is being treated for cancer in his liver and brain, said he has been making a recovery since taking a cancer drug known as Keytruda, which was created by Israeli doctors.
Carter has been a vocal critic of Israel.

The drug is believed to be the next generation of treatment for cancer.
Carter has not commented on the fact that this drug was made by Israeli doctors.

http://launch.newsinc.com/share.html?trackingGroup=92335&siteSection=freebeacon_hom_non_non_dynamic&videoId=29580503